Nascent Biotech Announces Pre-emptive Elimination of Significant Tranche of Convertible Debt

Rhea-AI Summary

Nascent Biotech, Inc. (OTCQB:NBIO) has successfully eliminated a significant convertible debt of over $186k held by JSJ Investments, LLC. This proactive measure prevents potential dilution of shares that could arise from the conversion of this debt into common shares at a discounted rate. CEO Sean Carrick emphasized the company’s commitment to shareholder value and reducing uncertainty in its financial standing. Nascent Biotech is focused on developing monoclonal antibodies for treating various cancers and viral infections, with ongoing clinical trials for their lead candidate, Pritumumab.

Positive

• Elimination of $186k convertible debt, preventing share dilution.
• Strengthens balance sheet and reduces financial uncertainty.
• Commitment to shareholder value emphasized by CEO.

Negative

• None.

SAN DIEGO, CA / ACCESSWIRE / April 26, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that It has paid off and eliminated a major convertible debt note, pre-emptively preventing a dilutive conversion.

The note, which was held by JSJ Investments, LLC ("JSJ"), represented over $186k in debt carried pre-conversion on the Company's balance sheet. Under the terms associated with the note, JSJ had the right to convert the value of the note into common shares at a substantial discount to current average trading levels in NBIO shares, which would have represented a significant dilutive event.

Instead, to prevent such an event and to reinforce its commitment to preserving shareholder value, the Company has paid off the full value of the note.

Nascent's CEO Sean Carrick stated, "We value our shareholders and our reputation as a shareholder friendly Company above all else. We have our sights set on some very big long-term objectives. And we won't get there by working against the interests of our common equity holders. Paying off this JSJ note reduces uncertainty and lightens the balance sheet. We look forward to identifying other opportunities to defend our shareholders' interests and avoid unnecessary dilution in financing our progress as we move toward full commercialization of monoclonal antibody solutions in the cancer and viral treatment markets."

About Nascent Biotech

Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies (mAbs) for the treatment of incurable cancers such as brain and pancreas, as well as hard-to-treat cancers such as colon and lung. Nascent is also employing its mAbs as part of treatments for dangerous viral infections, such as COVID-19. Collectively, cancers and viral infections afflict and kill tens of millions worldwide each year. Nascent's products are not commercially available. The Company's lead candidate, Pritumumab (PTB), is a fully human mAb that is in an FDA-approved Phase I clinical trial for the treatment of primary and metastatic brain cancer, including glioblastoma and malignant astrocytoma. Development of PTB as a potential treatment for COVID-19 has been initiated.

For further information please visit our website www.nascentbiotech.com.

Forward Looking Safe Harbor Statement

Statements in this press release about our future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Corporate Contact
Sean Carrick
President | CEO
Nascent Biotech, Inc.
772.713.0541 Cell
sean.carrick@nascentbiotech.com

Public Relations
EDM Media, LLC
https://edm.media

SOURCE: Nascent Biotech Inc.

View source version on accesswire.com:
https://www.accesswire.com/641861/Nascent-Biotech-Announces-Pre-emptive-Elimination-of-Significant-Tranche-of-Convertible-Debt

FAQ

What debt did Nascent Biotech eliminate?

Nascent Biotech eliminated over $186k in convertible debt held by JSJ Investments, LLC.

How does eliminating this debt affect NBIO shareholders?

Eliminating this debt prevents potential share dilution, thus protecting shareholder value.

What is the significance of the $186k convertible debt elimination?

The elimination prevents a substantial dilution of shares that could occur if the debt was converted at a discount.

What is Nascent Biotech's primary focus?

Nascent Biotech focuses on developing monoclonal antibodies for cancer and viral infections.

Is Nascent Biotech's lead product available commercially?

No, Nascent Biotech's products, including the lead candidate Pritumumab, are not commercially available yet.